FDA administration staff member restores position following dismissal instigated by Loomer
In a surprising turn of events, Dr. Vinay Prasad, a vocal critic of some FDA drug approvals and the government's response to the Covid-19 pandemic, has returned to his role at the Center for Biologics Evaluation and Research (CBER) at the Food and Drug Administration (FDA) [1]. His return comes weeks after his resignation amid pressure from political activists, including right-wing figure Laura Loomer, and criticism linked to his cautious approach to gene therapies and COVID-19 vaccine policies [5].
During his short tenure, Dr. Prasad faced high-profile disputes over gene therapy safety and a more evidence-focused, scientifically rigorous but conservative regulatory stance that limited COVID-19 vaccine recommendations to high-risk groups [2][3][4]. This approach sparked criticism from conservative media and activists, creating political pressure that possibly contributed to his departure [2][4]. The official reason given for his resignation was a desire not to distract from FDA work and to spend more time with family [1][2][4].
The FDA leadership, however, valued Dr. Prasad’s scientific rigor and regulatory contributions and reinstated him rapidly after his resignation, indicating a recognition of the importance of his role and expertise despite external political pressures [5]. Andrew Nixon, a Health and Human Services spokesperson, confirmed Dr. Prasad's return to CNN, but did not respond to questions about whether he will also return to his role as FDA chief medical and scientific officer [2].
Dr. Prasad's return has not been without controversy. Laura Loomer, who is granted extraordinary access to President Donald Trump, publicly attacked Dr. Prasad as a "progressive leftist saboteur" who was "undermining President Trump's FDA" [3]. Loomer has also threatened to "ramp up my exposes of officials within HHS and FDA" in the coming weeks [6].
Internal memos from May revealed that Dr. Prasad overrode FDA scientists on recommendations for two new versions of Covid-19 vaccines. The then-CBER director rebuked recommendations for broad use of the shots; the FDA eventually approved the vaccines for use in older and immunocompromised people but did not advise them for younger Americans who don't have underlying conditions [4].
As a hematologist oncologist, Dr. Vinay Prasad has made a significant impact in the medical community. However, his actions regarding the Covid-19 vaccines have drawn criticism from former officials and vaccine experts [7]. Former US Sen. Rick Santorum called Dr. Prasad "the man destroying @POTUS legacy for helping patients" [6].
This report was contributed by CNN's Meg Tirrell, Sarah Owermohle, and Adam Cancryn. As the story unfolds, it remains to be seen how Dr. Prasad's return will impact the FDA and the ongoing response to the Covid-19 pandemic.
References:
- CNN
- The Wall Street Journal
- The Hill
- STAT News
- KHN
- The Washington Post
In the realm of health and wellness, Dr. Vinay Prasad's return to the Center for Biologics Evaluation and Research (CBER) at the Food and Drug Administration (FDA) has sparked debates with medical-condition critics, including right-wing figure Laura Loomer. The political landscape surrounding Prasad's return is further complicated by Loomer's threats to escalate her criticisms of HHS and FDA officials, including the ongoing saga about gene therapies and COVID-19 vaccine policies. Simultaneously, general news outlets like CNN, The Wall Street Journal, STAT News, and The Washington Post have reported on this development, examining its potential impact on the FDA and the broader response to the Covid-19 pandemic.
